Bausch Health Reports 8.4% Q3 Surprise with $2.70B Sales, $1.21 EPS Estimates
Bausch Health beat earnings in two of the last four quarters, averaging a 6.26% negative surprise and delivering an 8.41% upside in the last period. Q4 estimates are $2.70 billion in sales and $1.21 EPS, with Zacks Rank #3 and Earnings ESP of -8.84% ahead of its Feb. 18 report.
1. Earnings Track Record
Bausch Health has shown mixed quarterly performance, beating earnings expectations in two of the past four periods and missing in the other two. Over those four quarters the company averaged a 6.26% negative earnings surprise, though it delivered an 8.41% upside in its most recent report.
2. Q4 Estimates and Key Drivers
For the fourth quarter, consensus forecasts call for $2.70 billion in revenues and $1.21 per share in EPS, while Bausch Health holds a Zacks Rank #3 and an Earnings ESP of -8.84%. Results will likely be driven by momentum in the Salix gastrointestinal franchise and Solta aesthetics business ahead of the Feb. 18 release.